RedHill Biopharma (RDHL) COO discloses RSUs, ADSs and option grants

Rhea-AI Filing Summary

RedHill Biopharma’s Chief Operating Officer Raday Gilead has filed an initial Form 3 reporting his equity holdings. He holds 30,758 unvested restricted share units, each linked to one American Depositary Share (ADS), and 4,537 ADSs that are convertible at any time with no expiration date.

The filing also lists several stock option grants to purchase Ordinary Shares: 250,000 and 400,000 shares with an exercise price of $5,000 per ADS, 600,000 shares at $4,870 per ADS, and 570,000 and 180,000 shares at $7,080 per ADS. Most option grants are described as fully vested and exercisable, with expirations between March 2028 and April 2031.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Raday Gilead

(Last) (First) (Middle)

21 HA'ARBA'A STREET

(Street)

TEL AVIV 6473921

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
RedHill Biopharma Ltd. [ RDHL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	307,580,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(2)	(2)	Ordinary Shares	45,370,000	(2)	D
Stock Option (Right to Buy)	(3)	(3)	Ordinary Shares	250,000	(3)	D
Stock Option (Right to Buy)	(4)	(4)	Ordinary Shares	400,000	(4)	D
Stock Option (Right to Buy)	(5)	(5)	Ordinary Shares	600,000	(5)	D
Stock Option (Right to Buy)	(6)	(6)	Ordinary Shares	570,000	(6)	D
Stock Option (Right to Buy)	(7)	(7)	Ordinary Shares	180,000	(7)	D

Explanation of Responses:

1. Represents 30,758 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.

2. Represents 4,537 ADSs, which are convertible at any time, at the holder's election and have no expiration date.

3. Represents stock option to purchase 250,000 Ordinary Shares (equivalent to 25 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on March 21, 2028.

4. Represents stock option to purchase 400,000 Ordinary Shares (equivalent to 30 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on May 6, 2029.

5. Represents stock option to purchase 600,000 Ordinary Shares (equivalent to 60 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $4,870 per ADS and the option expires on March 25, 2030.

6. Represents stock option to purchase 570,000 Ordinary Shares (equivalent to 57 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The 560,000 shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on April 28, 2031.

7. Represents stock option to purchase 180,000 Ordinary Shares (equivalent to 18 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on April 28, 2031.

	/s/ Gilead Raday	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does RedHill Biopharma (RDHL) COO Raday Gilead’s Form 3 report?

The Form 3 shows Raday Gilead’s initial beneficial ownership in RedHill Biopharma. It includes 30,758 unvested RSUs tied to ADSs, 4,537 ADSs convertible at any time, and multiple stock option grants over Ordinary Shares with specified exercise prices and expiration dates.

How many restricted share units does RDHL’s COO report on his Form 3?

Raday Gilead reports 30,758 unvested restricted share units, each linked to one American Depositary Share of RedHill Biopharma. These RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares, aligning the executive’s compensation with long-term shareholder value.

What American Depositary Share (ADS) holdings are disclosed for RDHL’s COO?

The filing discloses 4,537 American Depositary Shares held by Raday Gilead. According to the footnotes, these ADSs are convertible at any time at the holder’s election and have no expiration date, providing ongoing flexibility in how the position is maintained or adjusted.

What stock option grants over RedHill Biopharma Ordinary Shares are listed?

The Form 3 lists multiple stock option grants: 250,000, 400,000, 600,000, 570,000 and 180,000 Ordinary Shares. Footnotes state these were issued under the RedHill 2010 Option Plan, with most shares fully vested and exercisable and option expirations ranging from March 2028 to April 2031.

What are the exercise prices and expirations of RDHL COO’s stock options?

Exercise prices are stated as $5,000 or $4,870 per ADS for several grants, and $7,080 per ADS for two others. Expiration dates run from March 21, 2028 through April 28, 2031, defining the time window during which options may be exercised.

Are the stock options reported by RedHill Biopharma’s COO vested?

Footnotes explain that the shares underlying several stock options are fully vested and exercisable. For one 570,000-share grant, 560,000 shares are fully vested and exercisable. This means most of the reported option-based compensation is already available for exercise, subject to individual decisions.